MediWhale (CEO Choi Tae-geun) announced on the 3rd that its retina-based AI solutions 'Doctor Noon CVD' and 'Doctor Noon Funders' were designated as innovative products for 2025 by the Ministry of SMEs and Startups.
According to this designation, the two products can be supplied through private contracts with the government, public institutions, local governments, etc. for three years from June 27, 2025 to June 26, 2028. The innovative product system is operated to support the initial sales channels for products recognized for the technological and public nature of small and medium-sized enterprises and to promote entry into the public procurement market. Designated products are registered in the Public Procurement Service Innovation Marketplace, and various follow-up support such as public procurement consultations, matching with demand agencies, and product promotion are also provided.
Dr.Nun CVD is an AI-based software that analyzes retinal images to predict the risk of developing cardiovascular disease in the future. Its main feature is that it provides accuracy comparable to a cardiac CT in a non-invasive manner. This solution is being introduced and used by over 100 medical institutions around the world, including Severance Hospital, Dubai’s diabetes clinic ‘Glucare’, and Rome American Hospital under the Italian Nephrocenter.
Dr.Nun Fundus is an AI software that assists in the diagnosis of ophthalmic diseases. It provides the function to automatically detect signs of diseases such as glaucoma, retinal abnormalities, and media opacity based on retinal images.
MediWhale CEO Choi Tae-geun said, “Through the designation as an innovative product, both the public nature and marketability of our technology have been recognized,” and added, “We will work to expand distribution through public medical institutions so that more people can predict and prevent cardiovascular and metabolic diseases early through simple eye exams.”
- See more related articles
You must be logged in to post a comment.